ArticleJournal of applied clinical medical physics2026
A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A feasibility study of functional preservation in craniospinal irradiation with photon for pediatric medulloblastoma.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCraniospinal irradiation (CSI) is essential for treating pediatric medulloblastoma (MB) but causes significant long-term toxicities. Existing dose-reduction or partial-sparing strategies improve neurocognitive outcomes but may compromise survival or fail to address other late effects.
methodsA new functional preservation CSI (FP-CSI) technique was developed to spare the hippocampus, hypothalamic-pituitary axis (HPA), cochlea, and scalp while ensuring homogeneous vertebral coverage. Eight pediatric patients with average-risk MB were retrospectively planned with volumetric modulated arc therapy (VMAT) using both FP-CSI and standard CSI (S-CSI). Dosimetric parameters for the planning target volume (PTV) and organs at risk (OARs), radiobiological effects, plan robustness, plan complexity, and plan quality assurance (QA) were compared.
resultsFP-CSI significantly reduced mean doses to the hippocampus (12.4 vs. 23.9 Gy), hypothalamus (14.7 vs. 23.9 Gy), and pituitary gland (15.4 vs. 24.1 Gy, all p < 0.01). Vertebral dose gradients were halved (4.7 vs. 8.7 Gy). Moderate dose reductions were also achieved for the cochlea and scalp. Compared with S-CSI, FP-CSI exhibited slightly inferior PTV homogeneity (HI: 0.16 vs. 0.07) and conformity (CI: 0.88 vs. 0.93), but coverage remained clinically acceptable. Normal tissue complication probability (NTCP) modeling showed pronounced decreases in predicted neurocognitive and endocrine toxicity risks, with probability of neurocognitive impairment reduced from 84.5% to 24.9% and probability of endocrine dysfunction from 44.7% to 27.3%. FP-CSI increased modulation complexity and produced slightly lower gamma passing rates for cranial beams, while spinal beam deliverability remained similar to S-CSI. Robustness analysis indicated greater sensitivity of FP-CSI to setup and rotational errors. Nevertheless, 3D dose reconstruction confirmed accurate delivery, with volumetric dose deviations generally below 1 Gy.
conclusionFP-CSI effectively spares critical functional structures while maintaining clinically acceptable target coverage, and offers a promising strategy to reduce long-term radiotherapy-induced toxicities in pediatric MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.